Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS

v3.23.2
INTANGIBLE ASSETS
 6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

6.             INTANGIBLE ASSETS

 

The net carrying value of the identifiable intangible assets from all acquisitions as of June 30, 2023 and December 31, 2022 are as follows:

    

          As of
June 30, 2023		     As of
December 31, 2022		  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
                   
Asuragen acquisition:                      
Thyroid   9     $ 8,519     $ 8,519  
RedPath acquisition:                      
Pancreas test   7       16,141       16,141  
Barrett’s test   9       6,682       6,682  
                       
CLIA Lab   2.3       609       609  
                       
Total         $ 31,951     $ 31,951  
                       
Accumulated Amortization       (31,725 )     (31,090 )
                       
Net Carrying Value         $ 226     $ 861  

 

Amortization expense was approximately $0.3 million for both the three-month periods ended June 30, 2023 and 2022, and $0.6 million for the six-month periods ended June 30, 2023 and 2022, respectively. The remaining amortization expense of $0.2 million will be amortized in 2023.